Avalo Therapeutics, Inc.AVTXNASDAQ
Loading
Debt Growth AcceleratingAccelerating
Percentile Rank95
3Y CAGR+431.0%
5Y CAGR-9.4%
Year-over-Year Change
Year-over-year debt growth rate
3Y CAGR
+431.0%/yr
vs -35.7%/yr prior
5Y CAGR
-9.4%/yr
Recent acceleration
Acceleration
+466.7pp
Accelerating
Percentile
P95
Near historical high
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | 276.29% |
| Q2 2025 | -15.23% |
| Q1 2025 | 41.02% |
| Q4 2024 | 3.27% |
| Q3 2024 | 0.36% |
| Q2 2024 | 0.55% |
| Q1 2024 | 1.49% |
| Q4 2023 | 0.19% |
| Q3 2023 | -96.34% |
| Q2 2023 | -27.83% |
| Q1 2023 | 1.76% |
| Q4 2022 | 1.82% |
| Q3 2022 | 1.85% |
| Q2 2022 | -42.93% |
| Q1 2022 | 1.16% |
| Q4 2021 | 1.88% |
| Q3 2021 | 87.61% |
| Q2 2021 | 4782.63% |
| Q1 2021 | -16.20% |
| Q4 2020 | -82.12% |
| Q3 2020 | 452.06% |
| Q2 2020 | 0.00% |
| Q1 2020 | -100.00% |
| Q4 2019 | -99.05% |
| Q3 2019 | -0.70% |
| Q2 2019 | 7.74% |
| Q1 2019 | -0.16% |
| Q4 2018 | -0.16% |
| Q3 2018 | -0.16% |
| Q2 2018 | 0.32% |
| Q1 2018 | 0.00% |
| Q4 2017 | 0.00% |
| Q3 2017 | -100.00% |
| Q2 2017 | -59.29% |
| Q1 2017 | -36.59% |
| Q4 2016 | -26.21% |
| Q3 2016 | -20.30% |
| Q2 2016 | -16.48% |
| Q1 2016 | -13.84% |
| Q4 2015 | -12.06% |